Statins-Lipidomics
18 Nov 2020
Trial Summary
This study aims to aims to test whether treatment with simvastatin during docetaxel chemotherapy for metastatic castration-resistant prostate cancer can reverse a poor prognostic plasma lipid signature.
Acronym:
Statins-Lipidomics
ACTRN/NCT /ethics:
ACTRN12617000965303
Scientific title:
A multi-centre, open-label trial of simvastatin in addition to docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
Sponsor / Cooperative group:
Chris O’Brien Lifehouse
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | Prostate |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2018-05-01 |
| Anticipated End Date | 2021-03-31 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Francis Parnis |
| Recruitment Status | Recruiting |